Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

European disparities in access to cancer drugs

16.09.2008
New research has highlighted stark disparities in access to the latest cancer drugs across European Union nations, according to data presented at the 33rd Congress of the European Society for Medical Oncology (ESMO) in Stockholm.

While countries like France, Spain, Austria and Switzerland have tended to introduce the new drugs quickly, researchers say, others such as the UK and more recent EU entrants bring them in more slowly.

Dr Nils Wilking from the Karolinska Institute in Sweden gathered data on the sales of newer drugs per inhabitant of each country provided by pharmaceutical industry consultants IMS Health. His group’s focus was on the uptake of newer ’targeted‘ drugs over the past 10 years in 27 countries.

Overall, they found substantial variation between countries, both in terms of speed and uptake of newer cancer drugs, and the level of usage of the drugs.

... more about:
»IMS »Prevention »cancer drugs »radiotherapy

“Of the major western EU countries, the UK tends to come out both low and slow with a few exceptions,” Dr Wilking said. “Overall, Austria, Switzerland and France bring the new drugs out more quickly. France also has an especially high general uptake of most new drugs. Spain is somewhat lower and slower but was a ’leader‘ in the early part of the 2000s.”

The cost of the newer drugs is probably the major barrier to access, Dr. Wilking said. “To some extent it could also relate to the introduction of more ’targeted‘ drugs that tend to be more complex to understand and, in some cases, have smaller studies to support their approval.”

The impact of this disparity on the health of Europe’s cancer patients is hard to say with certainty, Dr Wilking said. “It is a complicated area as the epidemiological data lags so much behind. We need much better epidemiological data in order to evaluate the link between access to cancer drugs and outcome.”

Access to drugs is not the only factor involved in improving cancer outcomes, he added. “Patients need to have full access to the most innovative technologies in prevention, screening, surgery, radiotherapy and drugs.”

Vanessa Pavinato | alfa
Further information:
http://www.esmo.org

Further reports about: IMS Prevention cancer drugs radiotherapy

More articles from Health and Medicine:

nachricht 'Exciting' discovery on path to develop new type of vaccine to treat global viruses
18.09.2017 | University of Southampton

nachricht A new approach to high insulin levels
18.09.2017 | Schweizerischer Nationalfonds SNF

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Ultrafast snapshots of relaxing electrons in solids

Using ultrafast flashes of laser and x-ray radiation, scientists at the Max Planck Institute of Quantum Optics (Garching, Germany) took snapshots of the briefest electron motion inside a solid material to date. The electron motion lasted only 750 billionths of the billionth of a second before it fainted, setting a new record of human capability to capture ultrafast processes inside solids!

When x-rays shine onto solid materials or large molecules, an electron is pushed away from its original place near the nucleus of the atom, leaving a hole...

Im Focus: Quantum Sensors Decipher Magnetic Ordering in a New Semiconducting Material

For the first time, physicists have successfully imaged spiral magnetic ordering in a multiferroic material. These materials are considered highly promising candidates for future data storage media. The researchers were able to prove their findings using unique quantum sensors that were developed at Basel University and that can analyze electromagnetic fields on the nanometer scale. The results – obtained by scientists from the University of Basel’s Department of Physics, the Swiss Nanoscience Institute, the University of Montpellier and several laboratories from University Paris-Saclay – were recently published in the journal Nature.

Multiferroics are materials that simultaneously react to electric and magnetic fields. These two properties are rarely found together, and their combined...

Im Focus: Fast, convenient & standardized: New lab innovation for automated tissue engineering & drug

MBM ScienceBridge GmbH successfully negotiated a license agreement between University Medical Center Göttingen (UMG) and the biotech company Tissue Systems Holding GmbH about commercial use of a multi-well tissue plate for automated and reliable tissue engineering & drug testing.

MBM ScienceBridge GmbH successfully negotiated a license agreement between University Medical Center Göttingen (UMG) and the biotech company Tissue Systems...

Im Focus: Silencing bacteria

HZI researchers pave the way for new agents that render hospital pathogens mute

Pathogenic bacteria are becoming resistant to common antibiotics to an ever increasing degree. One of the most difficult germs is Pseudomonas aeruginosa, a...

Im Focus: Artificial Enzymes for Hydrogen Conversion

Scientists from the MPI for Chemical Energy Conversion report in the first issue of the new journal JOULE.

Cell Press has just released the first issue of Joule, a new journal dedicated to sustainable energy research. In this issue James Birrell, Olaf Rüdiger,...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

“Lasers in Composites Symposium” in Aachen – from Science to Application

19.09.2017 | Event News

I-ESA 2018 – Call for Papers

12.09.2017 | Event News

EMBO at Basel Life, a new conference on current and emerging life science research

06.09.2017 | Event News

 
Latest News

“Lasers in Composites Symposium” in Aachen – from Science to Application

19.09.2017 | Event News

New quantum phenomena in graphene superlattices

19.09.2017 | Physics and Astronomy

A simple additive to improve film quality

19.09.2017 | Power and Electrical Engineering

VideoLinks
B2B-VideoLinks
More VideoLinks >>>